PGI13 Direct Health Care Costs Associated With Opioid-Induced Constipation  by Lawson, R. et al.
A364  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
77% of total costs, with an average cost of R$ 67,319 per transplant. ConClusions: 
Organ transplant accounts for the majority of hospital health care costs in cirrhosis 
patients in the Brazilian public health care system. Considering patients with HCV 
treatment and cirrhosis, the average cost per patient was around 78% higher than 
the general cirrhosis patient.
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objeCtives: To assess the burden of hospitalizations related to Chronic Hepatitis 
C (CHC) in France in 2012 and to benchmark it to the 2009 estimate. Methods: All 
hospital stays with chronic viral hepatitis C (ICD-10 code B18.2) as principal, related 
or significantly associated diagnosis were extracted from the PMSI 2012 (French 
Medical Information System Program) database. Through an algorithm and a medi-
cal review, hospitalizations not related to CHC were excluded. Patients were assigned 
to a liver disease stage: F0-F3; compensated cirrhosis; decompensated cirrhosis; 
hepatocellular carcinoma; liver transplant. Same database and method (without 
making the distinction between compensated/decompensated cirrhosis) were used 
in 2009 allowing descriptive benchmark. Valuation was performed on French official 
tariffs for 2009 and 2012 and expressed in 2013 value (Euros). Results: 22,056 hos-
pitalizations were extracted in 2012 vs 27,258 in 2009 corresponding to 12,040 and 
15,482 patients, respectively. Sex-ratio M/F increased between 2009 and 2012 (1.66 
vs 1.78), as well as proportion of patients aged of 50 years old and over (60% vs 70%). 
In 2012, 5,834 patients were in F0-F3 fibrosis stage, 3,547 had cirrhosis and 2,105 
had hepatocellular carcinoma. Crude estimates for the evolution for these stages 
between 2009 and 2012 was -32%, -36% and +17%, respectively. Between 2009 and 
2012, number of liver biopsies was reduced by one third, and also less liver trans-
plants were performed (293 vs 254). Overall, the economic burden of hospitalizations 
related to CHC was € 60 millions in 2012, 8% lower than in 2009. ConClusions: 
3 major facts were highlighted: the decline in the number of liver biopsies, the 
decrease in the number of patients hospitalized for cirrhosis and the increase in 
patients hospitalized for hepatocellular carcinoma. This increase might be due to 
an improvement in screening techniques and aging of the population.
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objeCtives: To assess the mean annual cost of patients hospitalized for Chronic 
Hepatitis C (CHC) in France stratified by liver disease stage. Methods: Patients 
hospitalized for chronic viral hepatitis C (ICD-10 code B18.2) were identified in 
the PMSI-MCO 2010-2012 database (French Medical Information System Program- 
Medicine, Surgery, Obstetric) between January, 1st 2010 and December, 31st 2012 and 
tracked in the PMSI-SSR/HAD databases (post-acute care/hospitalizations at home: 
alternative management of care). An algorithm and a medical review excluded 
people under 18 years old, viral co-infected patients and non CHC related stays. 
During the study period, patients were followed from their first stay to censoring 
(i. e December 31st 2012 or death). For each patient, cumulative time in days in the 
different liver disease stages (F0-F3 fibrosis; compensated cirrhosis; decompensated 
cirrhosis; hepatocellular carcinoma; liver transplant) were calculated. Associated 
costs during these periods were added up and a mean annual cost per patient per 
liver disease stage estimated. As only inpatient deaths are captured into the PMSI, 
estimated outpatient deaths were imputed. Valuation was performed considering 
the national costs study (ENCC) expressed in 2013 Euro. Results: 58,405 stays 
were identified, extracted and considered as directly related to CHC corresponding 
to 26,621 patients. 743 additional hospitalizations were extracted from PMSI SSR/
HAD. Patients were 56±13.5 years old on average, 62% were male. Mean annual costs 
of patients hospitalized for CHC reason were: € 1,107 for F0-F3 fibrosis; € 2,104 for 
compensated cirrhosis; € 10,400 for decompensated cirrhosis; € 11,739 for hepatocel-
lular carcinoma; € 62,098 for 1st year of liver transplant and € 7,449 for subsequent 
year. ConClusions: CHC patients are mainly managed in acute care. Costs associ-
ated to CHC complications are important. These estimated hospital-related costs 
will be useful to populate cost-effectiveness and disease cost models.
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objeCtives: Opioid-induced constipation (OIC) is the most common and distress-
ing side effect of opioid treatment in patients with chronic pain. There are limited 
data to estimate the occurrence of OIC; however, estimates in non-cancer patients 
range from 40-50% and can be as high as 90% in cancer patients. Increased resource 
utilisation is associated with the diagnosis and management of OIC; however, the 
economic burden of OIC remains under-reported. Methods: This review con-
sidered the cost of illness associated with OIC. A targeted literature review was 
conducted for all publications since 2000 that evaluated the economic burden of 
OIC. Databases used for the literature search were PubMed, Embase, and HEED. 
All costs were converted to a 2014 USD cost base. Results: Eleven studies were 
identified which reported direct health care costs associated with OIC. All stud-
ies reported increased direct costs related to OIC; however, estimates per coun-
try varied significantly. Direct health care costs specifically related to OIC ranged 
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objeCtives: Biosimilar infliximab (CT-P13) is the first licensed biosimilar in EU for 
Crohn’s disease (CD). It is expected that spread of biosimilars in the treatment of 
CD will lead to cost savings and it might improve access to biological therapies. The 
main aim of this study was to analyse the budget impact of introducing biosimilar 
infliximab for the treatment of CD in six Central Eastern European (CEE) coun-
tries’ – Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia – health 
care systems. Methods: This budget impact model estimates potential impact of 
biosimilar infliximab on health care budget over three-year time frame from third-
party payer perspective. Spreadsheet-based country specific population model was 
developed functioning in quarter year time units. The model tracked movement of 
CD population between main states: 1) immune therapy, 2) infliximab, 3) biosimilar 
infliximab, 4) adalimumab. Switching between biologics and biosimilar infliximab 
was taken into consideration as well. In scenario analyses different rates of inter-
changing and switching were analysed. A -25% price difference was assumed for 
biosimilar infliximab compared to originator. Budget impact was calculated as dif-
ference in total cost of scenarios with and without biosimilar infliximab. Results: 
In 2013,4, 625 CD patients were treated with biologicals in the CEE. Over the 3-year 
period with gradually interchanging 80% of infliximab to biosimilar infliximab is 
expected to lead to a net benefit of 16,635,000 euros compared to the scenario in 
which biosimilar infliximab would not be available. In scenario in which inter-
changeabilty was disallowed the budget savings amounted to 7,842,000 euros. If 
budget savings were spent on reimbursement of additional biosimilar infliximab 
treatments, approximately further 889 or 420 patients could be treated in the six 
countries, respectively. ConClusions: Introduction of biosimilar infliximab treat-
ment for CD in CEE is predicted to bring substantial cost savings or increase of the 
number of patients with access to biological therapy.
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objeCtives: Originator products dominate the market, and as soon as patents 
expire prescribing patterns change as branded generics become the most often 
prescribed due to mandatory generic substitution in South Africa. This study inves-
tigated the prescribing patterns of proton pump inhibitors (PPIs). Methods: A 
retrospective, cross-sectional drug utilisation study was conducted on prescription 
data of a medical insurance scheme administrator in South Africa for 2011. The 
database contained 2 298 312 records for medicine, medical devices and proce-
dures. Results: A total of 22 198 PPIs were prescribed to 7 504 patients (average age: 
45.09 (SD= 15.82) years) at a cost of R3 931 241.43. The average cost per PPI prescrip-
tion was R177.10 (SD= R140.62). The average cost for a generic PPI prescription was 
R147.01 compared to R276.17 for a prescription for an originator product. Five differ-
ent PPIs were prescribed. Omeprazole, lansoprazole and pantoprazole had branded 
generics available on the market, whereas esomeprazole and rabeprazole only had 
originator products on the market. Omeprazole was the most frequently prescribed 
(47.05% of all PPI prescriptions). Nearly all (98.90%) omeprazole prescriptions were 
for one of its eight branded generics. Esomeprazole had the highest average cost 
per prescription of R289.23. The 40mg tablet formulation of esomeprazole was the 
most commonly prescribed. Less than 2% of PPI prescriptions were for rabeprazole. 
Most prescriptions were for Schedule 4 products (prescription-only), with only 3.91% 
Schedule 2 prescriptions (over-the-counter, prescribed in lower dosages for acute 
symptoms over a short period of time). Overall in this study, 76.70% of PPI prescrip-
tions were for branded generics. ConClusions: Omeprazole dominated PPI pre-
scribing, whilst esomeprazole was the most expensive PPI. It will be important to 
further investigate the impact of patent expiry and the introduction of new branded 
generics on PPI prescribing patterns. The study confirmed the significant price dif-
ferences for PPIs between branded generics and originator products.
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objeCtives: Estimate direct health care costs associated with cirrhosis from a bra-
zilian public payer perspective (SUS). Methods: A retrospective study of a public 
claims database (DATASUS) was used to assess direct health care costs associated 
with cirrhosis between 2008 and 2012. Patients with cirrhosis were identified based 
on ICD-10 codes (K70.3, K71.7, K74.3-K74.6). The retrospective analysis considered 
inpatient costs and outpatient treatment costs of patients during the 4 year time 
frame. Medication costs were defined as a weighted average during the period of 
analysis considering official government price lists available at www. compras-
net. gov. br. A sub analysis was carried out for cirrhotic patients with hepatitis C 
(HCV) treatment, defined as patients treated with peg-interferon with ribavirin 
(PR). Results: Between 2008-2012, 120,082 patients were hospitalized due to cir-
rhosis (49% of patients accounted by ICD K746) with a total treatment cost of R$ 404 
million, 68% accounting for transplant (R$ 276 million), 30% for outpatient proce-
dures (R$ 121 million), 2% for surgical procedures (R$ 6 million) and the remainder 
for exams and diagnostics. Patients were hospitalized for an average of 10,1 days 
per year, with an average cost of R$ 2,806 (R$2.149- R$ 3,757) per hospitalization 
event and R$ 3.378 (R$ 2.523-4.579) per patient. The average cost for transplant was 
R$ 52.912 (R$43.304-70.274). Between 2008 and 2012 2.933 patients were hospital-
ized for cirrhosis having received HCV treatment with a total cost of R$ 19 million. 
The average inpatient cost for HCV-cirrhosis patients was R$ 4,999 for 11,2 days of 
hospitalization. Organ transplants-associated costs accounted for R$ 15 million, 
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costs associated with the treatment of IBS in England. Methods: Hospital Episode 
Statistics (HES) data for 2012-13 for all clinical commissioning groups (CCGs) in 
England were analysed to calculate the tariff cost of IBS. IBS diagnosis codes were 
included in the analysis. Prescribing data and cost (PACT) data for 2012-13 were 
also analysed. Results: During 2012/13 there were 1,217,993 outpatient appoint-
ments in gastroenterology and colorectal surgery specialities, with a total tariff cost 
of £365,868,937. Despite this, only 1,982 patients were recorded with IBS-specific 
codes, with a total estimated tariff cost of £812,336. In addition, 28,849 patients 
were recorded with IBS-related symptom codes at a cost of £11,002,874. There were 
also 658,698 diagnostic lower GI endoscopies at a tariff cost of £169,676,704. Of 
these, 323,752 (49%) had no further follow-up in secondary care in the subsequent 
12 months. PACT data indicated that £44,977,959 and £25,582,752 was spent on 
selected laxatives and antispasmodics, respectively, commonly used to treat IBS in 
primary care. ConClusions: Despite being poorly clinically coded, it is clear that 
IBS places a significant cost burden on the NHS. Notably, 49% of patients seen for 
lower GI endoscopies had no further activity provided by the Hospital Provider Trust 
as an inpatient or outpatient over the subsequent 12 months, implying functional 
symptoms. Better diagnosis and subsequent management of IBS within a primary 
care setting may provide direct savings in the cost of IBS management. This study 
was financially supported by Almirall. Hospital Episode Statistics Data were pro-
vided via Harvey Walsh Ltd under commercial reuse licence.
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objeCtives: There are an estimated 620,000 patients with inflammatory bowel 
disease (IBD) in the UK. The rising incidence of IBD combined with its incurability 
has significant cost implications, with the National IBD Audit estimating that cost 
to the National Health Service (NHS) exceeded £1 billion in 2010. The aim of this 
cost of care model was to calculate the annual cost per patient of treating ulcerative 
colitis (UC) and Crohn’s disease (CD) from an NHS perspective, and to enable areas 
of potential cost savings to be explored. Methods: The cost of IBD was calculated 
by summing the costs of treatment, treatment side effects and disease-related com-
plications, accounting for the proportions of patients incurring these costs. The 
model included detailed costs for each treatment (eg. brand of mesalazine), major 
side effects for each treatment (eg. pancreatitis from thiopurines) and complica-
tions (eg. pyoderma gangrenosum). Default input values for costs, the percentage 
of patients receiving each treatment, and the percentage of patients experiencing 
side effects or complications were determined from national sources and published 
literature. However, the model permitted the user to input local or alternative data 
(eg. to reflect brand preferences for oral mesalazines) and conduct scenario analy-
ses. Results: Using default input values, the annual cost of treating any UC patient 
was estimated to be £3,084. For a UC patient in remission, in relapse with mild-to-
moderate UC or in relapse with severe UC, annual cost per patient was estimated 
to be £1,693, £2,903 and £10,760, respectively. The annual cost for any CD patient 
was estimated to be £6,156 (£1,800 for patients in remission; £10,513 for patients in 
relapse). ConClusions: IBD is a costly, chronic condition and this model facilitates 
calculation of annual costs per UC and CD patient. The models’ customisability will 
help hospitals to identify areas where savings could be made.
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objeCtives: To estimate health care resource use and costs associated with the man-
agement and treatment of constipation predominant irritable bowel syndrome (IBS-C) 
in Spanish clinical practice. Methods: The 2011 primary care (PC) IASIST database, 
which includes 3,678,522 clinical charts corresponding to PC sites from the National 
Health System (NHS), was used to estimate the number of patients with IBS-C (identi-
fied by a combination of ICD code and prescription of IBS-C drugs) and obtain data 
on the number of hospitalizations (service, frequency and duration), scheduled and 
emergency visits to PC, referrals to specialist care, and IBS-C treatments prescribed 
and dispensed in retail pharmacies and their associated costs. Based on data from 
IASIST database and unit costs retrieved from the e-Salud database, health care costs 
associated with IBS-C from the NHS perspective were calculated. Results: A total of 
5,649 IBS-C patients were indentified in the database, corresponding to a prevalence 
of 0.15% of patients attending PC. Total costs associated with IBS-C in the sample were 
estimated to be € 4,755,725; highest costs were associated with PC visits (€ 2,791,725, 
corresponding to 58.7% of total IBS-C costs). This high cost of PC visits is explained by 
the high number of visits by IBS-C patients (17.4 visits annually per patient). Costs of 
PC visits are followed by hospitalization costs (€ 610,859, 12.8% of total cost), medical 
visits to specialists (€ 556,164, 11.7%) and emergency room visits to PC (€ 491,142,10.3%). 
Costs of pharmacological treatment (€ 305,707) represented only 6.4% of total IBS-C 
costs. ConClusions: The low prevalence of IBS-C observed may be due to the under-
registration or under-diagnosis of IBS-C. Costs associated with the management of 
IBS-C are driven mainly by the high number of PC visits, which may be associated 
with the current unmet medical needs in IBS-C.
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from $1,747 to $48,782 per patient year. Per patient episode, direct costs associated 
with OIC ranged from $54 to $11,705. This was further supported by a large inter-
national study which reported significantly more physician visits and alternative 
care provider visits among patients with OIC than those without OIC. Two studies 
reported on a subgroup of patients with OIC who failed to respond to laxatives; 
these patients reported higher direct costs than patients who had a response to 
laxatives. ConClusions: The management of OIC is associated with potentially 
significant health care resource utilisation and financial burden. Patients with OIC 
incur higher direct health care costs than those without OIC and costs are increased 
further if patients with OIC have failed to respond to laxatives. There remains a 
paucity of data on health care resource utilisation in OIC and further research into 
the economic burden of OIC is needed.
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objeCtives: This study is the first study to assess the burden of IBS-C in 6 European 
countries (France, Germany, Italy, Spain, Sweden, UK). Here we present the results 
for Spain. Methods: Observational, retrospective-prospective (6 months each) 
study in patients diagnosed with moderate-to-severe IBS-C in the last five years 
(Rome-III criteria). Moderate-to-severe IBS-C was defined as IBS-Symptom Severity 
Score (IBS-SSS) ≥ 175. Quality-of-life (QoL) was assessed with EuroQoL-5D (EQ-5D) 
and IBS-QoL. Results: 112 patients were included (58% severe, mean age (±SD) 
46.8±13.7 years, 86% female). At baseline, symptom severity (IBS-SSS; severe > 300) 
was 315.4±82.9; presenteeism (WPA: IBS-C questionnaire; mean [±SD] % time in 
week prior to inclusion): 32.3±27.2; absenteeism: 6.1±15.8; work productivity loss: 
29.2±27.5; and daily activity impairment 39.6±27.2. Mean IBS-QoL was 41.0±21.2, 
(scale: 0-100 [best-to-worst]), and the most affected domains were “food avoidance” 
(mean: 60.4) and “health worry” (54.6). Mean EQ-5D was 57±21 (scale: 0-100 [worst-
to-best]) and 86% and 63% of patients reported moderate-to-severe problems in 
pain/discomfort, anxiety/depression respectively. The most prevalent symptoms 
were: constipation (84%), abdominal pain (80%), abdominal distention (80%) and 
bloating (59%). Over the year, 88% of patients consulted a primary care physician, 
and 82% a gastroenterologist; mean (95%CI): 3.8 and 2.3 visits, respectively. 20% of 
patients required emergency department visits or hospitalization (mean stay: 1.5 
(0.6-2.4) days). 58% of patients underwent a diagnostic test (mean: 2.4 (1.8-2.9)). 
85% of patients took pharmacological medication (80% took some pharmacological 
medication for their IBS-C) 30% received complementary therapies. After 6 months 
of follow-up, only 1 in 5 patients had no or mild symptoms. The mean (95%CI) annual 
direct cost for the Spanish National Health System (NHS) was 1067€ (730-1447) and 
the mean cost for the patient was 568€ (333-841). 13% of patients took sick leave 
(mean: 6.3 times; mean duration: 52 days) and 28% had productivity losses (mean: 
55 hours). Mean indirect costs were 1362€ (313-2866). Total costs amounted to 2997€ 
(1799-4515) /year. ConClusions: Moderate-to-severe IBS-C has a great impact on 
patient QoL, productivity, and health care resource utilization.
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objeCtives: The burden and cost of liver disease is known to be substantial, but accu-
rate data on this subject is still scarce in Portugal. So far most estimates are obtained 
from diagnosis-related groups (DRGs) associated with hospital financing and from 
expert panels. In this analysis we aimed to calculate the real costs associated with 
hospital admissions due to liver cirrhosis (LC) in a large hospital. Methods: All hos-
pitalizations in the gastroenterology department from a tertiary hospital in Portugal 
(Centro Hospitalar Lisboa Central) during 2012 were analyzed. Patient level data was 
used to retrieve relevant demographic and clinical information. Costs assumed to be 
specific for LC admissions, namely medication, imaging and other techniques, were 
estimated directly. Department-specific hospital accountancy was used to include 
the remaining hospital costs associated with these hospitalizations. Results: A 
total of 644 admissions were analyzed, from which 135 (21.0%) were due to LC, cor-
responding to 82 patients. 74.4% (n= 61) were males, median age was 55 years. The 
main cause of LC was alcohol (58.5%). In the admissions due to LC, average length 
of stay (LoS) was 15.3 days and total mean hospitalization cost was 3,979.5€ . For all 
analyzed admissions, average LoS and mean total cost were 8.1 days and 2,323.8€ , 
respectively. Average cost for medications in admissions for LC amounted to 492.7€ , 
compared to 228.7€ for all admissions. Within admissions for LC, costs were not 
significantly different for hospitalizations with or without hepatocellular carci-
noma. ConClusions: The estimated overall cost of a hospital admission for LC in 
a gastroenterology department was superior to the average value of hospitalizations 
for all causes, and approximately twice the official DRG value. This study highlights 
the current economic burden of liver cirrhosis faced by a tertiary hospital and the pos-
sible need to revise some of the assumptions used for financing Portuguese hospitals.
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objeCtives: The NHS is faced with increasing cost pressures that make the effi-
cient use of resources paramount. Patients with IBS may consume considerable 
NHS resource through inpatient and outpatient visits, diagnostic tests and treat-
ment. This study aimed to estimate admission costs and primary care prescribing 
